Although, the post-treatment mean serum MIF values were slightly lower in proliferative GN, both for the R versus NR and in non-proliferative GN for the R versus NR subgroups (i.e., 1.1 ± 0.7 vs. 2.4 ± 1.1 and 1.6 ± 0.8 vs.1.8 ± 0.9 ng/ml, respectively), the observed reductions were not statistically significant. The gene discussed is MIF; the disease is ganglioneuroma.